HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer

Cancer Letters

Volumn 354, Issue 1, 2014, Pages 97-106

  Park, Se Jin ^a   Kim, Jeong Kyu ^a   Bae, Hyun Jin ^a   Eun, Jung Woo ^a   Shen, Qingyu ^a   Kim, Hyung Seok ^a   Shin, Woo Chan ^a   Yang, Hee Doo ^a   Lee, Eun Kyung ^a   You, Jueng Soo ^b   Park, Won Sang ^a   Lee, Jung Young ^a   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

EGF receptor; Endocytosis; Histone deacetylase 6; Rabaptin 5

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; HISTONE DEACETYLASE 6; PROTEIN; RABAPTIN 5; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; MESSENGER RNA; RABEP1 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOSOME; GENE EXPRESSION; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; PROTEIN DEGRADATION; STOMACH CANCER; WESTERN BLOTTING; ENDOCYTOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RABAPTIN-5; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

EGF RECEPTOR; ENDOCYTOSIS; HISTONE DEACETYLASE 6; RABAPTIN-5;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; ENDOCYTOSIS; ENDOSOMES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; VESICULAR TRANSPORT PROTEINS;

EID: 84910011861     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.041     Document Type: Article

References (31)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
2. Zheng L., Wang L., Ajani J., Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004, 7:61-77.
3. Worthley D.L., Phillips K.D., Wayte N., Schrader K.A., Healey S., Kaurah P., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012, 61:774-779.
4. Gigek C.O., Chen E.S., Calcagno D.Q., Wisnieski F., Burbano R.R., Smith M.A. Epigenetic mechanisms in gastric cancer. Epigenomics 2012, 4:279-294.
5. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol 2008, 9:206-218.
6. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol 2011, 2011. 371832.
7. Kim J.K., Noh J.H., Eun J.W., Jung K.H., Bae H.J., Shen Q., et al. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol. Cancer Res 2013, 11:62-73.
8. Kim J.K., Noh J.H., Jung K.H., Eun J.W., Bae H.J., Kim M.G., et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013, 57:1055-1067.
9. Li Y., Shin D., Kwon S.H. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2013, 280:775-793.
10. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. J. Biomed. Biotechnol 2011, 2011. 875824.
11. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008, 68:7561-7569.
12. Saji S., Kawakami M., Hayashi S., Yoshida N., Hirose M., Horiguchi S., et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005, 24:4531-4539.
13. Jung K.H., Noh J.H., Kim J.K., Eun J.W., Bae H.J., Chang Y.G., et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012, 56:644-657.
14. Shan B., Yao T.P., Nguyen H.T., Zhuo Y., Levy D.R., Klingsberg R.C., et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J. Biol. Chem 2008, 283:21065-21073.
15. Gao Y.S., Hubbert C.C., Yao T.P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J. Biol. Chem 2010, 285:11219-11226.
16. Liu W., Fan L.X., Zhou X., Sweeney W.E., Avner E.D., Li X. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS ONE 2012, 7:e49418.
17. Wang Y., Roche O., Yan M.S., Finak G., Evans A.J., Metcalf J.L., et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med 2009, 15:319-324.
18. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
19. Tang J., Yan H., Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci. (Lond.) 2013, 124:651-662.
20. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
21. Sakuma T., Uzawa K., Onda T., Shiiba M., Yokoe H., Shibahara T., et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol 2006, 29:117-124.
22. Yoshida N., Omoto Y., Inoue A., Eguchi H., Kobayashi Y., Kurosumi M., et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004, 95:496-502.
23. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
24. Noh J.H., Jung K.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 2011, 6. e28103.
25. Xie H.J., Noh J.H., Kim J.K., Jung K.H., Eun J.W., Bae H.J., et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS ONE 2012, 7. e34265.
26. Rey M., Irondelle M., Waharte F., Lizarraga F., Chavrier P. HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur. J. Cell Biol 2011, 90:128-135.
27. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol 2006, 7:505-516.
28. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
29. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
30. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med 2004, 351:337-345.
31. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal 2009, 2:ra84.